A ccording to the National Comprehensive Cancer Network ([NCCN] , 2016), 6,590 new cases of acute lymphoblastic leukemia (ALL) were estimated to occur in 2016, along with 1,430 deaths. ALL is the most common cancer seen in children (Mullighan, 2012) . Among ALL classifications, lymphoblasts derived from B-cell lineages (B-cell precursor ALL [BCP-ALL]) represent the majority of these instances, with 88% of childhood ALL and 75% of adult ALL cases identified as B cell (NCCN, 2016) . Risk factors for the development of ALL can be found in Figure 1 . Childhood ALL has relatively good outcomes associated with diagnosis; about 80% of those diagnosed in childhood achieve long-term event-free survival (EFS), whereas adults with ALL typically have much poorer outcomes (National Cancer Institute [NCI], 2016b).
In addition to clinical factors, such as age and white blood cell count, cytogenetic and molecular techniques have been used to provide prognostic information regarding risk stratification and treatment response in patients with BCP-ALL. In addition, the NCCN (2016) has made treatment recommendations, including whether a patient should proceed with hematopoietic stem cell transplantation (HSCT) based on these cytogenetic and molecular risk classifications.
Various cytogenetic techniques (e.g., karyotyping, fluorescence in situ hybridization [FISH]) have identified several recurrent genetic aberrations in this population shown to correspond with poor outcome. These poor risk aberrations include BCR-ABL translocation (chromosome abnormality in which parts of separate chromosomes become rearranged), MLL rearrangements, hypodiploidy, and a complex karyotype (greater than five genetic abnormalities) (Moorman, 2012). Patients harboring one or more of these alterations are identified as being in a high-risk group (NCCN, 2016) . In contrast, patients with BCP-ALL found to have hyperdiploidy
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